International Stem Cell Corp. (ISCO) Gaining New Recognition for Its Work with Parkinson’s

When Agora Financial issued one of their Breakthrough Technology Alerts, it called ISCO stock “dirt-cheap at today’s prices, considering the technology it owns and the potential it could unlock.” ISCO’s October presentation at the American Neurological Association’s (ANA) 2013 annual meeting clarified some of that potential.

International Stem Cell Corp. is the developer of a revolutionary stem cell generation process called parthenogenesis, which avoids the controversial use of human embryos while at the same time greatly reducing the immune matching problems often associated with the use of donor stem cells. They are now showing the world some of the ways this dramatic new technology can be applied through their various therapeutic research programs, the primary one being the use of parthenogenesis for the generation of neural stem cells, research focused on the treatment of Parkinson’s disease.

Progress on ISCO’s Parkinson’s program was released in their recent presentation before the ANA, where Dr. R. Semechkin, ISCO’s Chief Scientific Officer, explained how their test results have now established a solid foundation for the clinical use of neural stem cells for the treatment of Parkinson’s, and also for the potential treatment of other neurological diseases, such as Alzheimer’s. ISCO research and tests show that their neural stem cells are able, after implantation, to effectively travel to the correct place in the brain, where they change into the type of neurons lost through the disease. In addition, they elicited a lower immunogenic response compared with other cell types.

ISCO is also actively engaged in work for the application of their stem cells to liver disease and the development of human corneas needed around the world for corneal transplants. Regarding the Parkinson’s program, the Agora Financial article emphasized that “The initiation of a Phase 1 trial in humans, and especially good data from that trial, will raise ISCO’s profile considerably. The trials are expected to begin in the middle of 2014.”

For additional information, visit www.InternationalStemCell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net